Zacks Research Has Positive View of Alkermes FY2025 Earnings

Alkermes plc (NASDAQ:ALKS - Free Report) - Stock analysts at Zacks Research boosted their FY2025 earnings per share estimates for Alkermes in a research report issued to clients and investors on Tuesday, July 1st. Zacks Research analyst R. Department now anticipates that the company will earn $1.55 per share for the year, up from their previous estimate of $1.54. The consensus estimate for Alkermes' current full-year earnings is $1.31 per share. Zacks Research also issued estimates for Alkermes' FY2026 earnings at $1.98 EPS, Q1 2027 earnings at $0.32 EPS, Q2 2027 earnings at $0.48 EPS and FY2027 earnings at $1.68 EPS.

Alkermes (NASDAQ:ALKS - Get Free Report) last posted its earnings results on Thursday, May 1st. The company reported $0.13 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.32 by ($0.19). Alkermes had a return on equity of 27.52% and a net margin of 23.30%. The firm had revenue of $306.51 million during the quarter, compared to the consensus estimate of $307.53 million. During the same quarter in the previous year, the company earned $0.43 EPS. The business's revenue was down 12.6% compared to the same quarter last year.

A number of other analysts also recently commented on ALKS. HC Wainwright reaffirmed a "neutral" rating on shares of Alkermes in a research report on Friday, May 2nd. Royal Bank Of Canada raised their target price on Alkermes from $39.00 to $40.00 and gave the company a "sector perform" rating in a research report on Friday, May 2nd. Deutsche Bank Aktiengesellschaft lifted their target price on Alkermes from $40.00 to $52.00 and gave the stock a "buy" rating in a research note on Thursday, March 27th. Needham & Company LLC initiated coverage on shares of Alkermes in a research report on Wednesday, May 28th. They set a "buy" rating and a $45.00 price target for the company. Finally, Wall Street Zen downgraded shares of Alkermes from a "strong-buy" rating to a "buy" rating in a report on Monday, May 5th. Three research analysts have rated the stock with a hold rating, nine have given a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average target price of $40.00.

Alkermes Stock Performance

NASDAQ:ALKS traded down $0.25 on Thursday, hitting $28.75. The stock had a trading volume of 1,122,189 shares, compared to its average volume of 1,733,696. Alkermes has a 1 year low of $22.90 and a 1 year high of $36.45. The firm's fifty day simple moving average is $30.12 and its two-hundred day simple moving average is $30.89. The stock has a market cap of $4.74 billion, a P/E ratio of 13.76, a price-to-earnings-growth ratio of 1.79 and a beta of 0.44.

Insiders Place Their Bets

In related news, SVP Christian Todd Nichols sold 3,334 shares of Alkermes stock in a transaction that occurred on Tuesday, June 10th. The shares were sold at an average price of $31.09, for a total value of $103,654.06. Following the completion of the transaction, the senior vice president directly owned 86,208 shares in the company, valued at approximately $2,680,206.72. The trade was a 3.72% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Corporate insiders own 4.40% of the company's stock.

Hedge Funds Weigh In On Alkermes

Several hedge funds have recently made changes to their positions in ALKS. JPMorgan Chase & Co. grew its holdings in Alkermes by 488.6% during the 1st quarter. JPMorgan Chase & Co. now owns 5,234,995 shares of the company's stock valued at $172,860,000 after buying an additional 4,345,523 shares in the last quarter. Avoro Capital Advisors LLC purchased a new position in Alkermes during the fourth quarter valued at approximately $70,462,000. Nuveen LLC purchased a new position in Alkermes during the first quarter valued at approximately $66,689,000. Norges Bank purchased a new position in Alkermes during the fourth quarter valued at approximately $56,684,000. Finally, RTW Investments LP grew its position in shares of Alkermes by 13.6% during the 4th quarter. RTW Investments LP now owns 7,557,835 shares of the company's stock valued at $217,363,000 after purchasing an additional 903,802 shares in the last quarter. 95.21% of the stock is currently owned by hedge funds and other institutional investors.

About Alkermes

Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders.